Ashley A Eggman1, Daniel J Feaster, Jared A Leff, Matthew R Golden, Pedro C Castellon, Lauren Gooden, Tim Matheson, Grant N Colfax, Lisa R Metsch, Bruce R Schackman. 1. From the *Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY; †Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, FL; ‡Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY; §Public Health-Seattle and King County, Seattle, WA; and ¶San Francisco Department of Public Health, San Francisco, CA.
Abstract
INTRODUCTION: Rapid HIV testing in high-risk populations can increase the number of persons who learn their HIV status and avoid spending clinic resources to locate persons identified as HIV infected. METHODS: We determined the cost to sexually transmitted disease (STD) clinics of point-of-care rapid HIV testing using data from 7 public clinics that participated in a randomized trial of rapid testing with and without brief patient-centered risk reduction counselingin 2010. Costs included counselor and trainer time, supplies, and clinic overhead. We applied national labor rates and test costs. We calculated median clinic start-up costs and mean cost per patient tested, and projected incremental annual costs of implementing universal rapid HIV testing compared with current testing practices. RESULTS: Criteria for offering rapid HIV testing and methods for delivering nonrapid test results varied among clinics before the trial. Rapid HIV testing cost an average of US $22/patient without brief risk reduction counseling and US $46/patient with counseling in these 7 clinics. Median start-up costs per clinic were US $1100 and US $16,100 without and with counseling, respectively. Estimated incremental annual costs per clinic of implementing universal rapid HIV testing varied by whether or not brief counseling is conducted and by current clinic testing practices, ranging from a savings of US $19,500 to a cost of US $40,700 without counseling and a cost of US $98,000 to US $153,900 with counseling. CONCLUSIONS: Universal rapid HIV testing in STD clinics with same-day results can be implemented at relatively low cost to STD clinics, if brief risk reduction counseling is not offered.
RCT Entities:
INTRODUCTION: Rapid HIV testing in high-risk populations can increase the number of persons who learn their HIV status and avoid spending clinic resources to locate persons identified as HIV infected. METHODS: We determined the cost to sexually transmitted disease (STD) clinics of point-of-care rapid HIV testing using data from 7 public clinics that participated in a randomized trial of rapid testing with and without brief patient-centered risk reduction counseling in 2010. Costs included counselor and trainer time, supplies, and clinic overhead. We applied national labor rates and test costs. We calculated median clinic start-up costs and mean cost per patient tested, and projected incremental annual costs of implementing universal rapid HIV testing compared with current testing practices. RESULTS: Criteria for offering rapid HIV testing and methods for delivering nonrapid test results varied among clinics before the trial. Rapid HIV testing cost an average of US $22/patient without brief risk reduction counseling and US $46/patient with counseling in these 7 clinics. Median start-up costs per clinic were US $1100 and US $16,100 without and with counseling, respectively. Estimated incremental annual costs per clinic of implementing universal rapid HIV testing varied by whether or not brief counseling is conducted and by current clinic testing practices, ranging from a savings of US $19,500 to a cost of US $40,700 without counseling and a cost of US $98,000 to US $153,900 with counseling. CONCLUSIONS: Universal rapid HIV testing in STD clinics with same-day results can be implemented at relatively low cost to STD clinics, if brief risk reduction counseling is not offered.
Authors: Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Bruce R Schackman; Tim Matheson; Moupali Das; Matthew R Golden; Shannon Huffaker; Louise F Haynes; Susan Tross; C Kevin Malotte; Antoine Douaihy; P Todd Korthuis; Wayne A Duffus; Sarah Henn; Robert Bolan; Susan S Philip; Jose G Castro; Pedro C Castellon; Gayle McLaughlin; Raul N Mandler; Bernard Branson; Grant N Colfax Journal: JAMA Date: 2013-10-23 Impact factor: 56.272
Authors: Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark Journal: MMWR Recomm Rep Date: 2006-09-22
Authors: Lytt I Gardner; Lisa R Metsch; Pamela Anderson-Mahoney; Anita M Loughlin; Carlos del Rio; Steffanie Strathdee; Stephanie L Sansom; Harvey A Siegal; Alan E Greenberg; Scott D Holmberg Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: M L Kamb; M Fishbein; J M Douglas; F Rhodes; J Rogers; G Bolan; J Zenilman; T Hoxworth; C K Malotte; M Iatesta; C Kent; A Lentz; S Graziano; R H Byers; T A Peterman Journal: JAMA Date: 1998-10-07 Impact factor: 56.272
Authors: Bruce R Schackman; Ashley A Eggman; Jared A Leff; Megan Braunlin; Uriel R Felsen; Lisa Fitzpatrick; Edward E Telzak; Wafaa El-Sadr; Bernard M Branson Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Parastu Kasaie; W David Kelton; Rachel M Ancona; Michael J Ward; Craig M Froehle; Michael S Lyons Journal: Acad Emerg Med Date: 2017-11-11 Impact factor: 3.451
Authors: Anne M Neilan; Raphael J Landovitz; Mylinh H Le; Beatriz Grinsztejn; Kenneth A Freedberg; Marybeth McCauley; Nattanicha Wattananimitgul; Myron S Cohen; Andrea L Ciaranello; Meredith E Clement; Krishna P Reddy; Emily P Hyle; A David Paltiel; Rochelle P Walensky Journal: Ann Intern Med Date: 2022-02-01 Impact factor: 51.598
Authors: Lorraine T Dean; Madeline C Montgomery; Julia Raifman; Amy Nunn; Thomas Bertrand; Alexi Almonte; Philip A Chan Journal: Am J Prev Med Date: 2018-02-01 Impact factor: 5.043
Authors: Ali Jalali; Danielle A Ryan; Kathryn E McCollister; Lisa A Marsch; Bruce R Schackman; Sean M Murphy Journal: J Subst Abuse Treat Date: 2020-03
Authors: Hannah K Knudsen; Jennifer Cook; Michelle R Lofwall; Sharon L Walsh; Jamie L Studts; Jennifer R Havens Journal: Subst Abuse Treat Prev Policy Date: 2017-08-16
Authors: Anne M Neilan; Richard Dunville; M Cheryl Bañez Ocfemia; Joshua A Salomon; Jordan A Francke; Alexander J B Bulteel; Li Yan Wang; Katherine K Hsu; Elizabeth A DiNenno; Rochelle P Walensky; Robert A Parker; Kenneth A Freedberg; Andrea L Ciaranello Journal: J Adolesc Health Date: 2018-01 Impact factor: 5.012
Authors: Anne M Neilan; Alexander J B Bulteel; Sybil G Hosek; Julia H A Foote; Kenneth A Freedberg; Raphael J Landovitz; Rochelle P Walensky; Stephen C Resch; Pooyan Kazemian; A David Paltiel; Milton C Weinstein; Craig M Wilson; Andrea L Ciaranello Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Ethan D Borre; Emily P Hyle; A David Paltiel; Anne M Neilan; Paul E Sax; Kenneth A Freedberg; Milton C Weinstein; Rochelle P Walensky Journal: J Infect Dis Date: 2017-10-17 Impact factor: 7.759